- Report
- September 2025
- 250 Pages
Global
From €3957EUR$4,490USD£3,408GBP
- Report
- April 2025
- 200 Pages
Global
From €3957EUR$4,490USD£3,408GBP
- Report
- March 2025
- 175 Pages
Global
From €3957EUR$4,490USD£3,408GBP
- Report
- February 2025
- 200 Pages
Global
From €3957EUR$4,490USD£3,408GBP
- Report
- February 2025
- 200 Pages
Global
From €3957EUR$4,490USD£3,408GBP
- Report
- August 2025
- 195 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 187 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 198 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 184 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 194 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 198 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 188 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- August 2025
- 189 Pages
Global
From €3124EUR$3,545USD£2,691GBP
€3471EUR$3,939USD£2,990GBP
- Report
- September 2025
- 487 Pages
Global
From €5155EUR$5,850USD£4,441GBP
- Report
- September 2025
- 168 Pages
Global
From €5155EUR$5,850USD£4,441GBP
- Report
- February 2025
- 150 Pages
Global
From €3393EUR$3,850USD£2,923GBP
€4274EUR$4,850USD£3,682GBP
- Report
- November 2024
- 150 Pages
Global
From €3393EUR$3,850USD£2,923GBP
€4274EUR$4,850USD£3,682GBP
- Report
- July 2025
- 350 Pages
Global
From €4361EUR$4,949USD£3,757GBP
- Report
- May 2023
- 150 Pages
Global
From €5243EUR$5,950USD£4,517GBP
- Report
- October 2022
- 118 Pages
Global
From €3965EUR$4,500USD£3,416GBP

Iodine-123 is a radioactive isotope of iodine used in Nuclear Medicine and Radiopharmacology. It is used in a variety of medical imaging procedures, such as thyroid scans, to diagnose and treat thyroid diseases. It is also used in the diagnosis of certain types of cancer, such as neuroendocrine tumors. Iodine-123 has a short half-life of 13.2 hours, making it ideal for use in Nuclear Medicine. It is produced in nuclear reactors and cyclotrons, and is available in a variety of formulations, including capsules, solutions, and injectables.
Companies in the Iodine-123 market include GE Healthcare, Mallinckrodt Pharmaceuticals, Jubilant DraxImage, and Bracco Diagnostics. Show Less Read more